{"title":"组织细胞增生症与眼科创新并行发展。第三十一届爱德华-杰克逊纪念讲座。","authors":"Jasmine H Francis","doi":"10.1016/j.ajo.2024.10.030","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To highlight innovations in ophthalmic oncology through histiocytosis advancements.</p><p><strong>Design: </strong>Perspective and retrospective review.</p><p><strong>Methods: </strong>The literature outlining the recent advancements in histiocytosis and ocular oncology was reviewed and combined with trial data and personal recollection. Intersections between these two fields were discussed.</p><p><strong>Results: </strong>The understanding of genetic mutations in disease-both in which cells they occur and the timing of mutation development-has expanded in tandem for the fields of ophthalmic oncology and histiocytosis. Similarly, advancements in diagnostic and treatment technology in one field can help patients in the other. For example, in one study, cell-free DNA testing reliably detected mutations in 14 of 18 (78%) patients with suspected histiocytosis. This technique has also been used in ophthalmic oncology as an alternative to invasive biopsy to avoid the risk of tumor externalization, vision impairment, and other side effects. These and other advancements have allowed both fields to utilize targeted agents to successfully treat diseases with an actionable mutation; or deliver more targeted chemotherapy via the intraarterial technique.</p><p><strong>Conclusions: </strong>The explosion of molecular genetics technology and targeted therapies has revolutionized cancer treatment, including histiocytosis and ophthalmic oncology. Recent progress in both fields has shown how these seemingly disparate areas have many intersections, and this speaks to the collaborative spirit that is inherent in clinical research.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":"104-118"},"PeriodicalIF":4.1000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Histiocytosis Advancements Parallel Ophthalmic Innovations: The LXXXI Edward Jackson Memorial Lecture.\",\"authors\":\"Jasmine H Francis\",\"doi\":\"10.1016/j.ajo.2024.10.030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To highlight innovations in ophthalmic oncology through histiocytosis advancements.</p><p><strong>Design: </strong>Perspective and retrospective review.</p><p><strong>Methods: </strong>The literature outlining the recent advancements in histiocytosis and ocular oncology was reviewed and combined with trial data and personal recollection. Intersections between these two fields were discussed.</p><p><strong>Results: </strong>The understanding of genetic mutations in disease-both in which cells they occur and the timing of mutation development-has expanded in tandem for the fields of ophthalmic oncology and histiocytosis. Similarly, advancements in diagnostic and treatment technology in one field can help patients in the other. For example, in one study, cell-free DNA testing reliably detected mutations in 14 of 18 (78%) patients with suspected histiocytosis. This technique has also been used in ophthalmic oncology as an alternative to invasive biopsy to avoid the risk of tumor externalization, vision impairment, and other side effects. These and other advancements have allowed both fields to utilize targeted agents to successfully treat diseases with an actionable mutation; or deliver more targeted chemotherapy via the intraarterial technique.</p><p><strong>Conclusions: </strong>The explosion of molecular genetics technology and targeted therapies has revolutionized cancer treatment, including histiocytosis and ophthalmic oncology. Recent progress in both fields has shown how these seemingly disparate areas have many intersections, and this speaks to the collaborative spirit that is inherent in clinical research.</p>\",\"PeriodicalId\":7568,\"journal\":{\"name\":\"American Journal of Ophthalmology\",\"volume\":\" \",\"pages\":\"104-118\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ajo.2024.10.030\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajo.2024.10.030","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:通过组织细胞增生症的进展突出眼科肿瘤学的创新:设计:透视和回顾性综述:方法:对概述组织细胞增生症和眼肿瘤学最新进展的文献进行回顾,并结合试验数据和个人回忆。讨论了这两个领域的交叉点:结果:眼肿瘤学和组织细胞增生症领域对基因突变在疾病中的作用--包括突变发生在哪些细胞中以及突变发生的时间--的了解同步加深。同样,一个领域诊断和治疗技术的进步也能帮助另一个领域的患者。例如,在一项研究中,无细胞 DNA 检测能可靠地检测出 18 名疑似组织细胞增生症患者中 14 人(78%)的基因突变。这种技术还被用于眼科肿瘤学,作为侵入性活检的替代方法,以避免肿瘤外化、视力受损和其他副作用的风险。这些和其他方面的进步,使这两个领域都能利用靶向药物成功治疗具有可作用突变的疾病;或通过动脉内技术提供更有针对性的化疗:结论:分子遗传学技术和靶向疗法的迅猛发展为包括组织细胞增生症和眼科肿瘤学在内的癌症治疗带来了革命性的变化。这两个领域的最新进展表明,这些看似互不相关的领域其实有很多交叉点,这也体现了临床研究中固有的合作精神。
Histiocytosis Advancements Parallel Ophthalmic Innovations: The LXXXI Edward Jackson Memorial Lecture.
Purpose: To highlight innovations in ophthalmic oncology through histiocytosis advancements.
Design: Perspective and retrospective review.
Methods: The literature outlining the recent advancements in histiocytosis and ocular oncology was reviewed and combined with trial data and personal recollection. Intersections between these two fields were discussed.
Results: The understanding of genetic mutations in disease-both in which cells they occur and the timing of mutation development-has expanded in tandem for the fields of ophthalmic oncology and histiocytosis. Similarly, advancements in diagnostic and treatment technology in one field can help patients in the other. For example, in one study, cell-free DNA testing reliably detected mutations in 14 of 18 (78%) patients with suspected histiocytosis. This technique has also been used in ophthalmic oncology as an alternative to invasive biopsy to avoid the risk of tumor externalization, vision impairment, and other side effects. These and other advancements have allowed both fields to utilize targeted agents to successfully treat diseases with an actionable mutation; or deliver more targeted chemotherapy via the intraarterial technique.
Conclusions: The explosion of molecular genetics technology and targeted therapies has revolutionized cancer treatment, including histiocytosis and ophthalmic oncology. Recent progress in both fields has shown how these seemingly disparate areas have many intersections, and this speaks to the collaborative spirit that is inherent in clinical research.
期刊介绍:
The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented online at www.AJO.com and on ScienceDirect.
The American Journal of Ophthalmology publishes Full-Length Articles, Perspectives, Editorials, Correspondences, Books Reports and Announcements. Brief Reports and Case Reports are no longer published. We recommend submitting Brief Reports and Case Reports to our companion publication, the American Journal of Ophthalmology Case Reports.
Manuscripts are accepted with the understanding that they have not been and will not be published elsewhere substantially in any format, and that there are no ethical problems with the content or data collection. Authors may be requested to produce the data upon which the manuscript is based and to answer expeditiously any questions about the manuscript or its authors.